Background /Aims: Recent studies of microRNA (miRNA) involvement in tumorigenesis have indicated the critical role of these non-coding small RNAs in malignant transformation, but the prognostic role, if any, of miRNAs in breast cancer remains undetermined. Therefore, we assessed the prognostic significance of microRNA-9 (miR-9) and miR-221 in breast cancer toward the goal of understanding the contribution(s) of these miRNAs to cancer cell stemness. Methods: The level of each of miR-9 and miR-221 in 206 paired laser capture microdissected tumor cells and non-tumor cells was determined by quantitative reverse transcription-PCR (qRT-PCR). The relationship between the miRNA signature and clinicopathological data and prognosis of breast cancer was assessed. Identification of a stem cell-enriched side population was achieved with fluorescence-activated cell sorting and a sphere-forming assay. Wound healing, Boyden chamber assays, and western blotting were used to study the contribution of each miRNA to tumor cell migration and invasion. Results: We found that induction of miR-9 and miR-221 mimics conferred side-population cells to form spheroidal tumor colonies in suspension culture that maintained the mesenchymal stem-cell potential in non-invasive MCF-7 breast cancer cells. In contrast, knockdown of both miR-9 and miR-221 in invasive MDA- MB-231 breast cancer cells dramatically decreased the number of side-population colonies with stem cell-like potency, which reduced the capacity for tumor-cell renewal, invasion, and migration. Clinically, the mean proportion of miR-9-or miR-221-overexpressing cells was significantly greater in tumor cells compared with non-tumor cells (P < 0.05). Increased levels of miR-9 and miR-221 in breast tissue portended a significantly elevated risk of progression to malignancy with respect to larger tumor size, poor differentiation, late-stage evolution, lymph-node metastasis (P < 0.05), and lower overall survival (P trend = 0.017; eight-year followup). Conclusion: Our findings provide strong evidence that miR-9 and miR-221 can enhance the generation of cancer stem cells to yield an invasive phenotype and that overexpression of these miRNAs predicts a poor outcome for breast cancer patients.
Introduction
Breast cancer is the second leading cause of cancer death among women worldwide, and the prevalence and mortality rates are high in Western countries. Nevertheless, previous work has helped to define the clinicopathologic features of breast cancer, such as histological grade, lymph-node involvement, and status of hormone receptors, which have improved prognostic evaluation and guided therapeutic approaches for the disease [1, 2] . The malignant transformation of tumor cells occurs via a multistep process that involves the reprogramming of pluripotency, which is considered the most challenging issue facing therapeutic intervention [3] . Side-population (SP) cells constitute an enriched source of cancer-initiating cells with an increased capacity to efflux anti-cancer drugs via the transporter of the ATP-binding cassette (ABC) superfamily, such as the ABC subfamily G member 2 encoded by ABCG2, the overexpression of which serves as a hallmark of cancer stem cells [4, 5] . SP cells constitute a distinct subpopulation of cancer cells that are similar to normal adult stem cells that reside in regenerative tissues, and they share many stemness properties such as the capacity for self-renewal, regeneration, and re-differentiation [6] . The epithelial-to-mesenchymal transition (EMT), which commonly occurs during tumorigenesis, regulates SP cell behavior with respect to the potential to undergo hyperproliferation, local invasion, and distant metastasis and develop resistance to apoptotic stimuli within the renewable tumor clone [7] [8] [9] . Thus, a better understanding of the biomarkers that link the EMT with the generation of SP cells will allow prognoses to be more effective and inform treatment strategies for breast cancer.
MicroRNAs (miRNAs) are a class of short, non-coding RNAs (18-25 nucleotides) that bind the 3'-untranslated region of target mRNAs and thereby serve as post-transcriptional modulators of gene expression. There has been a growing attention to address the role of miRNAs as promoters or suppressors which regulate a vast range of physiological responses in tumor progression [10, 11] , especially, for their functions in regulating the cellular levels of tens to hundreds of mRNAs and can affect many biological pathways, including those involved in the reprogramming of pluripotent stem cells [12] [13] [14] . As such, we hypothesized that deregulation of miRNAs that are expressed specifically in stem cells that reside among SP cells could promote the EMT and thereby potentiate metastatic disease. Recent studies of microRNA-9 (miR-9) and microRNA-221 (miR-221) suggest their involvement in oncogenesis and EMT activation as well as in the enhancement of the metastatic phenotypes observed in various types of human cancer [15, 16] . However, it remains unknown whether the EMT can be reactivated by these two miRNAs in SP cells to acquire the mesenchymal phenotypes that are characteristic of breast cancer cells, and thus the clinical significance of miR-9/221 overexpression is unclear with respect to the outcomes of breast cancer patients. Therefore, we evaluated the fates of stem cell-like cells derived from breast tumors in which miR-9 and/or miR-221 had been up-or downregulated in vitro. We also report clinical information concerning the differential expression of miR-9 and miR-221 in tumor cells compared with non-tumor cells to inform the prognosis of patients in our breast cancer study cohort beyond the standard eight-year follow-up.
cells per well for 24 h and grown to 60% confluency. Used at 20 nM, the mirVana™ miRNA mimics, miRNA inhibitors, or negative control (Ambion, Life Technologies, Austin, TX) formed transfection complexes with Lipofectamine®2000 (Invitrogen, Carlsbad, CA) in a serum-free Opti-MEM® medium (Invitrogen) at 37°C for 24 h. The medium was exchanged daily with fresh medium with 10% FBS. Cell lysates were harvested post-transfection for total RNA isolation.
SP cell sorting
We followed detailed protocols for SP cell sorting [17] . Briefly, the dissociated cells were suspended at a concentration of 2 × 10 6 cells/mL in SP medium (calcium-and magnesium-free Hanks' balanced salt solution with 2% FBS, 1% penicillin/streptomycin, and 10 mM HEPES, pH 7.4. Hoechst 33342 (Sigma-Aldrich) was optimized (concentration of 5 μg/mL) in SP medium with intermittent mixing for 90 min at 37°C. The specific ABCG2 inhibitor, reserpine (50 μM final concentration; Sigma-Aldrich), was introduced prior to the addition of Hoechst 33342 to inhibit dye efflux. The dye Hoechst 33342 was excited at a wavelength of 355 nm, and fluorescence profiles were measured by dual-wavelength analysis with emission for Hoechst 33342 blue at 450 nm and Hoechst 33342 red at 675 nm. After that, SP and non-SP cells were separately maintained on ice in the dark for fluorescenceactivated cell sorting (FACS Digital Vantage/Diva cell sorter; BD Biosciences, San Jose, CA) (Fig. 1) .
Sphere passage
Spheres formed of SP cells in culture were collected and washed to remove serum and then incubated in serum-free DMEM containing 100 IU/ mL penicillin, 100 μg/mL streptomycin, N-2 plus media supplement (R&D Systems Inc. Minneapolis MN), 10 ng/mL EGF, 20 ng/mL bFGF (Invitrogen), and 4 mg/mL heparin (Sigma). For serial passage of spheroid cells, single cells were cultured in lowattachment 6-well plates (Corning Inc., Corning, NY), and the cell density at each passage was adjusted to 5 × 10 3 cells/mL in the serum-free medium.
Wound healing assay Approximately 1.5 × 10 5 cells per well were seeded in 24-well culture plates. Cells were transfected with miRNA mimics or miRNA inhibitors, after which a sterile 10-μL tip was used to scratch the monolayer of cells to create a narrow wound-like gap. The plate was kept at 37°C, 5% CO 2 for 24 h. Microscopy images of a representative field of the cell-free space were taken at 0 and 18 h after the scratch, and cell migration distance was calculated with Image Pro plus software (Media Cybernetics, Silver Spring, MD). Transwell migration upper chambers were filled with culture medium containing 2% FBS, and the lowerchamber medium contained 10% FBS. The chamber was stained with Giemsa for 1 h and then washed twice with distilled/deionized H 2 O. Non-migrating cells were removed from the cotton, and migrated cells were counted in five randomly selected fields from each well using a light microscope (Olympus Ckx41; Tokyo, Japan).
Western blotting
Western blotting was carried out as described [18] . Proteins that had been separated by SDS-PAGE were transferred onto a polyvinylidene difluoride membrane that was then subjected to western blotting with an appropriate primary antibody against the following: human vimentin (Cell Signaling Technology, Danvers, MA), fascin and β-catenin (Santa Cruz Biotechnology, Dallas, TX), and Claudin-1 (CLDN-1) and CLDN-2 (Novus Biologicals, Littleton, CO). The antibody against GAPDH (Cell Signaling Technology) served as the endogenous control to normalize the expression of proteins of interest. For western blotting, an appropriate horseradish peroxidase-conjugated secondary antibody was used, and each immunoreactive protein was visualized with an enhanced chemiluminescence assay (Western Blotting Luminol Reagent; Santa Cruz Biotechnology). Band intensity was quantified by densitometry (Digital Protein DNA Imagineware, Huntington Station, NY).
Patients and tissue specimens
All frozen-tissue specimens were histologically confirmed to be primary invasive ductal carcinoma of the breast and were from 206 patients enrolled between 1999 and 2005. All participants provided written informed consent to participate in this study. Considerations regarding methodological issues, including research design, sampling scheme, and consent procedure, were approved by the Ethics Committee of the Institutional Review Board at the Chung Shan Medical University Hospital, Taichung, Taiwan. During surgical intervention, freshly resected breast tumor tissues were immediately frozen in liquid nitrogen until analysis. None of the patients received neo-adjuvant treatment before primary surgery, thus avoiding any consequent effects on the expression levels of the miRNA examined. Tumor grade was categorized according to the Nottingham modification of the Scarff-Bloom-Richardson system [19] , and tumor pathology was classified according to the sixth edition of the AJCC Cancer Staging Manual [20] . The presence of metastatic tumor cells in lymph nodes was scored by immunohistochemical staining of at least 10 lymph-node dissections from tumors of patients. Details of their clinicopathological features were obtained from hospital tumor registries.
Laser capture microdissection and quantitative PCR (qPCR) analysis
We followed detailed procedures for RNA isolation from cells collected by laser capture microdissection [18, 21] . RNAs were extracted from laser capture microdissected samples from the tumor and adjacent nontumor breast tissue of each patient using the mirVana miRNA isolation kit, and the RNA concentration in each sample was quantified using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Waltham, MA). A single-tube TaqMan TM MicroRNA assay (Applied Biosystems, Foster City, CA) was used to quantify mRNA level using the StepOnePlus TM instrument (Applied Biosystems); the sequences for probes and primer sets used to detect miR-9 (ID 000583) and miR-221 (ID 000524) in the MicroRNA assay were purchased from Applied Biosystems. The level of U6 small RNA (encoded by RNU6B) was stable and reproducible across tissue specimens and was applied to estimate differential expression of the miRNAs between tumor and non-tumor paired samples in each case. Relative expression levels were calculated using the 2 -ΔΔCt method.
Prognostic significance of miR-9/221 in breast cancer
This study was dependent on a reliable follow-up system that we established and maintained to actively and regularly track cancer progression for our breast cancer patients [22] . Disease-free survival (DFS) was measured as the time from surgery to recurrence/mortality or the end of the study, and overall survival (OS) was calculated from the date of surgery to the date of disease-related death or date of the last follow-up for each patient, at which time ~93% (191 of 206) of patients were analyzed. For assessing the accuracy of the miRNA in demonstrating the progression of breast tumors, the diagnostic cut-off for miRNA was identified based on receiver-operating characteristic curves and the estimated area under the curve, to which an optimal cutoff point was applied to differentiate the increased level of each miRNA in tumors. The quantified miRNA levels were converted into binary measurements according these cutoffs. The odds ratio (OR) and 95% confidence interval (CI) were estimated with a logistic regression model to investigate the association between clinical pathological parameters or prognostic features of tumors and the level of miR-9 and/or miR-221. We also used this system to examine whether overexpression of either of these two miRNAs could be prospectively associated with breast cancer progression using the eight-year OS and DFS as outcomes of interest. The hazard ratio (HR) and 95% CI were estimated with the Cox proportional hazards model and Kaplan-Meier method, which were used to correlate OS and DFS with clinical pathological parameters or miRNA levels. All statistical tests were two-sided, and P < 0.05 was considered statistically significant.
Statistical analysis
Data are presented as the mean ± standard deviation (S.D.). For all groups, all cell-based experiments were performed in triplicate. The statistical significance of difference in results between test groups was assessed with an unpaired two-tailed Student's t-test, one-way ANOVA, Mann-Whitney U test or Dunnett's test as appropriate. All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL). P-values are represented as *, <0.05; **, <0.01; and ***, <0.001.
Results

Blockade of miR-9 and miR-221 decreases SP generation and inhibits breast cancer cell invasion/migration
We found that the endogenous expression of both miR-9 and miR-221 was significantly greater in the aggressive MDA-MB-231 breast cancer cell line than in the non-invasive MCF-7 breast cancer line ( Fig. 2A) . To determine whether there is a causal link between miR-9 and miR-221 expression and the abundance of cancer stem cell-like SP cells in breast cancer, we identified and purified SP cells using the dye Hoechst 33342 and fluorescence-activated cell sorting of breast cancer cells treated with reserpine. This SP sorting procedure revealed that the proportion of SP cells was significantly reduced in MDA-MB-231 cells transfected with a specific inhibitor of miR-9 (anti-miR-9) or miR-221 (anti-miR-221) (or both inhibitors) compared with a mock-transfected control ( Fig. 2B and 2C ). Upon transfection of cells with both miRNA inhibitors, the number of tumorsphere-forming MDA-MB-231 cells was reduced by >80% together with a reduction in the transcription of the stemness markers CD133, Nanog, and Oct4 genes ( Fig. 2D and 2E) . Moreover, inhibition of miR-9 or miR-221 led to a diminution of the typical elongated and spindle-like fibroblastic phenotype of MDA-MB-231 cells (Fig. 2G ). In addition, transfection with either inhibitor dramatically decreased the motility of MDA-MB-231 SP cells (Fig. 2F ) in conjunction with a 40-70% decrease in their invasion capacity (Fig. 2H) .
Overexpression of miR-9 and miR-221 enhances invasion and metastasis of MCF-7 SP cells
Because the levels of endogenous miR-9 and miR-221 were low in the non-invasive MCF-7 breast cancer cells, we investigated the effects of miR-9 and/or miR-221 mimics on these cells to elucidate the stem-cell mechanisms by which overexpression of miR-9 and miR-221 enhances invasion and metastasis of breast cancer. As expected, the percentage of SP cells was increased by >4-fold in miR-9/221-transfected MCF-7 cells compared with mock-transfected controls (miR mimic negative control, NC; Fig. 3A and 3B) . These results were reinforced by wound-healing assays of the miR-9/221-transfected MCF-7 SP cells, which revealed a 2-to 3-fold increase in motility (Fig. 3C) and a 3-to 5.5-fold increase in invasion capacity (Fig. 3D) . Moreover, the levels of the mesenchymal proteins: vimentin, fascin, and β-catenin were higher in MCF-7 cells transfected with both miR-9 and miR-221 (Fig. 3E) . In parallel, use of specific inhibitors of the two miRs (i.e., anti-miR-9 and anti-miR-221) resulted in increased expression of the epithelial proteins CLDN-1 and CLDN-2 in the E-cadherin-deficient MD-MBA-231 cells compared with expression in the negative control cells (NC; Fig. 3E ). Again, these findings supported our hypothesis that miR-9 and miR-221 enable breast cancer cells to generate SP cells with stem cell-like characteristics, which is considered a prerequisite for retention of invasive potential during the EMT.
Overexpression of miR-9/221 is associated with poor prognosis of breast cancer patients
Given that overexpression of the two miRNAs in vitro led to the generation of cancer stem cell-like cells that promote tumor invasion, we examined the association between miR-9 and miR-221 levels and clinicopathological characteristics of breast cancer. For this Table 1 . We used laser capture microdissection to isolate tumor cells from tissue specimens to avoid contamination with normal cells and then quantified the level of individual miRNAs by real-time qPCR. Comparative quantification of miRNA levels revealed that miR-9 and miR-221 were expressed at significantly higher levels in tumors compared with matched-pair nontumor tissue (normalized against RNU6B; mean values (-DCt) for miRNA level among tumors and non-tumor tissues were 3.06 vs. 1.78, respectively, for miR-9, P < 0.0001, and 1.47 vs. 0.50 for miR-221, P = 0.0002; Fig. 4A ). To establish the prognostic significance of both miRNAs, we determined the cutoff for expression of each miR using receiver-operating characteristic (ROC) curves to discriminate late-stage breast tumors (stage III/IV) from early-stage tumors (stage I/II) (Fig 4B) .
Based on these curves, we defined ''overexpression'' of miR-9 and miR-221 by comparing the levels of these miRs in tumor cells relative to non-tumor cells, which revealed a 4.35-fold cutoff value for miR-9 (-DDCt = 2.12) and 5.10-fold cutoff value for miR-221 (-DDCt = 2.35). These cutoff values were used to assess the association between miRNA overexpression and clinicopathological features, manifesting as risk elevation for miR-9 or miR-221 in tumors, with subsequent assignment of each tumor as poorly differentiated, late stage, and nodal involvement (positive for lymphnode metastasis, LNM) after adjusting for age and expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth-factor receptor 2 (HER2) in a multivariate logistic regression analysis (all P < 0.05; Table 2 ).
We found that both miRNAs were overexpressed in advanced-stage breast tumors, and this predicted a poor clinical outcome for those patients. As expected, tumor cell invasiveness was most prevalent in the subgroup that co-overexpressed both miR-9 and miR-221, as assessed with a multivariate analysis (P < 0.05; Table 3 ). The use of a dummy-variable coding scheme and the β estimate from the regression model revealed a significant tendency for elevated risk of breast cancer development in that patient subgroup (all P trend < 0.05, Table 3 ).
Overexpression of miR-9 and miR-221 predicts poor survival of breast cancer patients
We evaluated the significance of miR-9/miR-221 overexpression as a predictor of clinical outcome for breast cancer patients during an eight-year follow-up. Similar to known prognostic factors, including tumor size, histology grade, tumor stage, and tumor extension to lymph nodes ( Fig. 5A-H) , the primary tumors that carried both miR-9 and miR-221 overexpression were predictive of shorter OS and DFS, as determined by significant differences in the two Kaplan-Meier curves with the Bonferroni correction ( Fig. 5I and 5J ; P-values for the log rank test were smaller than 0.001 and 0.035 for OS and DFS, respectively). Of the prognostic factors, tumors that were poorly differentiated, late stage or LNM-positive were associated with disease mortality as assessed with a univariate Cox proportional regression analysis (P < 0.05, Table 4 ). Moreover, comparison of the miRNA expression profiles for the breast cancer (Table 4) .
Discussion
It is well established that the EMT correlates with epithelial cell plasticity and is associated with the characteristics of latestage tumorigenesis, such as local tumor invasion and metastasis. A growing body of evidence suggests that activation of the EMT has a close connection with the development of stem cell-like characteristics of mesenchymal cells in the cancer niche [23, 24] . In our present study, we first assessed the generation of SP cells, which was promoted by miR-9 and miR-221 overexpression in non-invasive MCF-7 cells. We also found that the wounded area in our wound-healing assay was reduced in cells transfected with miR-9 or miR-221 as compared with miR mimic-transfected control cells. By contrast, knockdown of miR-9 and miR-221 led to decreased production of SP cells and resulted in decreased invasiveness of MDA-MB-231 breast cancer cell line. Similarly, in studies of recurrent glioma, SP cells were screened for hierarchical organization within the new tumor clone because this subpopulation has stem cell-like characteristics and plasticity that are critical for tumor reprogramming to a more aggressive tumor phenotype [25, 26] . Taken together, these findings provide evidence for a causal link between the regulatory role of miRNAs in establishing the cancer stemcell phenotype, highlighting the relevance of differential expression of such miRNAs in a paradigm that distinguishes between benign and invasive features of carcinomas, including those of breast cancer, based on the generation of SP cells. Studies have demonstrated that cancer cells acquire the ability to invade and disseminate via dysregulation of miRNA expression, which promotes the EMT [13, [27] [28] [29] . Increased levels of miR-9 and miR-221 in tumor cells are reportedly associated with an increased risk for tumorigenesis and greater resistance to chemotherapeutics, as demonstrated in multiple primary cancers [15, [30] [31] [32] . Recent work predicted targets of miR-9 and defined their functions, such as EMT induction by targeting the CDH1 mRNA [33, 34] , mediation of temozolomide resistance of glioblastoma multiforme cells [35, 36] , and SP expansion and metastasis through loss of α-catenin in squamous cell carcinoma [32] . Moreover, epigenetic modulation of miR-221 contributes to stemness by decreasing DNMT3b expression and promotes cell outgrowth and invasiveness of human breast cancer stem cells via downregulation of PTEN and Trichorhinophalangeal syndrome type 1 (TRPS1) [16, 37, 38] . Our present results demonstrate that induction of miR-9/221 promotes the generation of cancer stem cell-like cells and help explain the heterogeneity of the invasion/dissemination capacity of SP cells present in breast cancer niches. Notably, recent reports have shown that delivery of miR-9 in tumor tissues in vivo could reduce angiogenesis and metastasis in gastric, melanoma, and nasopharyngeal carcinomas [39] [40] [41] . These discrepancies in the reported results may be due to differences in the extracellular microenvironment that tumor cells encounter because of tissue-specific regulation. Consequently, the shift of the paradigm of cancer-related association studies from a single candidate miRNA to multiple miRNAs, as was the case in our present study of breast cancer patients, is helping define prognostic signatures that can be validated in different cancer types.
The use of ER, PR, and HER2 has become a common and acceptable way for clinicians to predict breast cancer prognosis and prescribe a suitable therapeutic regimen for women living with the disease [42, 43] . A recent investigation of miRNAs in stem-cell biology revealed the involvement of miR-200 in the organization of miRNA clusters and its differential expression in human breast cancer stem cells compared with normal mammary stem cells; therefore, a better understanding of the molecular mechanisms underlying the miR-200 family miRNAs with respect to how their cellular levels and consequent loss of control of self-renewal and EMT in breast cancer stem cell-like cells can predict patient prognosis [44] . Hereby, we expanded our previous dataset from a cell model to clinical observation to demonstrate that the prognostic significance of miR-9 and miR-221 overexpression in breast cancer progression is independent of ER, PR, and HER2, as demonstrated by our findings, as follows. First, we found that elevated cellular levels of miR-9 and miR-221 could drive cancer stemness and contribute to the invasiveness in MCF-7 cells that expressed ER/PR/HER2. Second, decreased expression of both miRNAs reflects a divergence of cancer stemness in a triple-negative breast cancer cell line, such as MDA-MB-231, to inhibit cell invasion and migration through repression of the EMT. Third, within the confines of the reliability of the inferred statistical significance of the clinical prognosis, the data obtained from our breast cancer cohort revealed that miR-9 and miR-221 are promising biomarkers that could clearly delineate the chance for survival and adjusted mortality after simultaneously considering the immunohistochemical markers of ER, PR and HER2. These findings are consistent with previous reports of miR-9 and miR-221 overexpression in primary tumors from patients with subsequent metastasis as compared with those of metastasis-free patients across several cancer types [45] [46] [47] [48] as well as prognostic implications for recurrence in patients with papillary thyroid carcinoma [49] . Collectively, these findings shed light on the potential value of miR-9 and miR-221 testing with regard to helping clinicians establish the most effective therapeutic regimen for their breast cancer patients.
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